Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 77Melanoma 57Carcinoma, Renal Cell 44Small Cell Lung Carcinoma 33Colorectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Transitional Cell 24Neoplasms 23Triple Negative Breast Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 17Mesothelioma 17Pancreatic Neoplasms 15Mesothelioma, Malignant 15Stomach Neoplasms 13Breast Neoplasms 13Uterine Cervical Neoplasms 12Urinary Bladder Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Merkel Cell 10Kidney Neoplasms 9Adenocarcinoma of Lung 8Esophageal Neoplasms 7Endometrial Neoplasms 7Lymphoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Prostatic Neoplasms 5

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Risk Resectable NSCLC × Nivolumab × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡